ID H0777

Adds approximately 20 new substances to Schedule I controlled substances, including bromazolam, various fentanyl analogs (beta-methylacetyl fentanyl, meta-fluorofuranyl fentanyl, ortho-chlorofentanyl, para-chlorofentanyl, tetrahydrothiofuranyl fentanyl), and nitazene derivatives (N-desethyl isotonitazene, N-piperidinyl etonitazene)

Changes controlled substance registration requirements from annual to biennial renewal and adds noroxymorphone to Schedule II, norfentanyl as an immediate precursor to fentanyl, and brexanolone and serdexmethylpheniate to Schedule IV

Modifies prescription drug monitoring program database access from mandatory ("must") to permissive ("may") language and consolidates three separate criminal misdemeanor provisions for database misuse into a single reorganized subsection

Updates administrative provisions including allowing the Board of Pharmacy to automatically mirror disciplinary actions taken by federal DEA or state professional licensing boards against a registrant's controlled substance privileges

Declares an emergency effective date of July 1, 2026